Medical Brands (Amsterdam) and Decas Botanical Synergies (Carver, MA) have earned EU medical device status for their Cranberry-Active Bladder Capsules, intended to treat or prevent urinary tract infections (UTIs).
Medical Brands (Amsterdam) and Decas Botanical Synergies (Carver, MA) have earned EU medical device status for their Cranberry-Active Bladder Capsules, intended to treat or prevent urinary tract infections (UTIs).
The European Food Safety Authority (EFSA; Parma, Italy) recently rejected a health claim for cranberries and defense against bacterial pathogens. That rejection, soon to enter into law, can only help the market success of Cranberry-Active Bladder Capsules.
Antibiotics still remain a viable market alternative for UTI health, but published science indicates that their use can lead to the body’s increased resistance of other antibiotics.
“As a registered Class IIa medical device, Cranberry-Active is the only cranberry-based product in the European Economic Area and recognized countries that can be freely marketed with a medical claim for treating and preventing urinary tract infections,” said the two companies in a joint press release.
Medical Brands and Decas will present an information seminar on their product at Vitafoods Europe in Geneva later this month (Tuesday, May 22, 2pm).
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.